Abstract: Many normal physiological and disease-related pathophysiological processes are regulated by the interactions of complex signaling networks of pro-and anti-inflammatory markers, growth factors, soluble receptors and extracellular matrix proteins, as well as other cell-cell signaling proteins, which we define collectively as cytokines. Because multiple cell-cell signaling factors may be involved in a single biological process, detection of expression of multiple cytokines is essential to unraveling the mechanisms and effects of many disease processes. Cytokine antibody arrays have been developed to meet this growing demand for multiplexed protein detection. In particular, discovery and validation of diseaserelated protein biomarkers require high-throughput detection of many proteins simultaneously. This review will address the complexity of cytokine biology, discuss current and future antibody array technologies and explore their applications in cytokine biomarker discovery and validation for variety of human diseases. Specific examples of these applications will be presented, including the search for cytokine biomarkers related to neurological and neurodegenerative diseases (such as autism and Alzheimer's), immunological disorders (including asthma), and various cancers.
INTRODUCTION
Cytokines are among the most intensely studied protein families in biomedical science, with tens of thousands of publications devoted to exploring their myriad functions and potential applications in biomedicine. In addition to playing critical roles in many normal cellular events, cytokines are implicated in the initiation and development of almost every major life-threatening disease. For this reason, cytokines have long been explored as potential disease biomarkers.
Evaluation of cytokine expression levels, ideally by cytokine expression profiling, is a critical step in biomarker discovery and development process. Although enzymelinked immunosorbent assay (ELISA) is the most common method and the gold standard for measurement of individual cytokine expression levels, the key to successfully identifying promising new biomarkers is the simultaneous detection of multiple cytokines.
To meet this challenge, cytokine antibody arrays have been developed and, in many cases, successfully utilized in the discovery of biomarkers and key disease-related molecules. Antibody arrays enable the researchers to profile multiple cytokine levels from trace amounts of biospecimens, an approach which holds great promise for biomarker discovery. Other multiplex technologies, such as aptamer arrays and suspension bead assays, may also be used for cytokine profiling; however, only planar cytokine antibody array technologies and their applications in biomarker discovery will be the focus of this review. 
THE COMPLEXITY OF CYTOKINE BIOLOGY
Cytokines are typically regarded as pro-or antiinflammatory markers, such as chemokines, or as secreted proteins that induce an immunomodulatory response. However, it is useful to consider these molecules in a broader context. A better definition of a cytokine may be any secreted protein-distinct from non-peptide neurotransmitters and traditional peptide hormones-that generates or transmits cell-cell signals. This diverse group of molecules includes growth and differentiation factors, pro-and antiangiogenic factors, adipokines, and extracellular matrix proteins (for specific examples, see Table 1 ). These proteins, collectively, are responsible for a number of physiologic processes, including inflammation [1] , immune response [2] ; [3] , cell migration [4] and tissue infiltration [5] , angiogenesis [6] , adipogenesis [7] , apoptosis [8] , wound healing [9] , immune cell maturation [10, 11] , hematopoiesis [12] and cell growth, proliferation and differentiation of other cell types [13] .
Moreover, cytokines play a prominent role in many diseases. In cancer, for example, various cytokines can promote tumorigenesis, angiogenesis, invasion, metastasis and tumor growth and proliferation [14, 15] . Cytokines mediate pathogenic inflammatory and immunomodulatory functions in cancer [14] and many other diseases, including auto-immune diseases, such as rheumatoid arthritis, psoriasis, multiple sclerosis, systemic lupus erythematosus, type 1 diabetes, Crohn's disease and other inflammatory bowel diseases. Recently, it has been suggested that chronic inflammation plays a key role in neurodegenerative diseases, such as Alzheimer's [16] and Parkinson's diseases [17] , insulin resistance and type 2 diabetes [18] , atherosclerosis [19] ; [1] and other cardiovascular diseases [1] . Since cytokines play a pivotal role in the pathology of many diseases, a number of approved treatments either target cytokines or are recombinant cytokines themselves ( Table  1) . Several important cytokine targets are the epithelial growth factor receptor (EGFR/ErbB1) and heregulin-2 (HER2/neu/ErbB2) receptors, which are overexpressed in many tumors [20] , and tumor necrosis factor alpha (TNF ), which is a key pro-inflammatory protein in many autoimmune diseases [21] . Examples of approved recombinant cytokine biologics are interferon-alpha (IFN ), which is used to treat chronic viral hepatitis [22] and AIDS-related Kaposi's Sarcoma [23] , or interferon-beta (IFN ), which is used in treating multiple sclerosis [24] .
Many cytokines are pleiotropic, meaning that a single cytokine may induce a wide range of effects in various cell and tissue types [25] . Interleukin-6 (IL-6), for example, was originally characterized as a factor in B-cell differentiation [26] . Subsequent investigations have identified pleiotropic effects of IL-6 in functions as diverse as proliferation of hematopoietic stem cells, maturation of macrophages and T cells, induction of acute phase response in the liver and stimulation of neuronal development and osteoclast formation [27] .
The function of cytokines is often redundant, wherein multiple cytokines have similar effects on a single cell type [25] . For example, both leukemia inhibitory factor (LIF) and oncostatin M (OSM) share with IL-6 the capacity to inhibit the growth of murine myeloid leukemia cells and the ability to induce them to differentiate into macrophages. All of these molecules share protein sequence homology with each other and with IL-11, ciliary neurotrophic factor (CNTF) and cardiotropin-1 (CT-1). The receptors of these cytokines also share sequence homology, and signal transduction of these ligand-receptor complexes requires recruitment of a membrane-bound protein, gp130 [27] .
Induction, modification and regulation of these extracellular signals are accomplished through complex interactions with other cytokines. Often, the biological effects of cytokines on a single cell depend upon multiple, simultaneous signal inputs from different cytokines. The net effects of cytokine-cytokine interactions can be additive, antagonistic, synergistic, sequential, dose-dependent, intracrine, autocrine or paracrine [28] . In antigen-presenting dendritic cells, for example, high expression levels of IL-12 are dependent on signals elicited by both CD40 ligand and interferon-gamma (IFN ). while CD40 signaling was sufficient to induce secretion of tumor necrosis factor alpha (TNF ) and IL-8 from dendritic cells [29] .
Additionally, the activities of cytokines are modulated by a complex network of various binding proteins, inhibitors, and soluble receptors. The latter appears to be a common mechanism of regulation for many secreted cell-cell signaling proteins [30] . Cytokines exert their influence by binding to membrane-associated receptors. However, many cytokine receptors exist as soluble factors, secreted from the cell by a number of mechanisms, including proteolytic cleavage of the extracellular domain from the cell surface (as seen with TNF, IL-1 and M-CSF receptors) or expression of alternatively spliced transcripts (as seen with IL-4, Il-5 , IL-7 and LIF receptors). The importance of the modulatory functions of soluble receptors is suggested by the tight regulation of these processes and their conservation in human, rodent and avian species [30] .
In sum, the complexity of cytokine biology necessitates consideration of the expression of multiple cytokines. For this reason, multiplexed protein detection assays are a critical tool for success in illuminating the mechanisms of cytokinedriven processes.
ANTIBODY ARRAY TECHNOLOGY
The complexity of cytokine networks and the limitations of single-analyte detection methods (ELISA, Western blot, etc.) have prompted the development of a more highly parallel approach to measure multiple cytokine levels. Among the multi-analyte technologies that have emerged over the last decade, antibody arrays are one of the most attractive and promising methods.
The design principle of antibody arrays is usually based on either a sandwich immunoassay or a direct-labeling approach. The sandwich format requires a pair of antibodies: one immobilized (capture antibody) and one in solution (detection antibody) (Fig. 1A) ; this method has the advantages of excellent specificity and sensitivity. However, the combinations and the number of antibody pairs in each array are both limited by occasional cross-reactivity between detection antibodies. For this reason, the practical limit on the number of antibody pairs that can be included in one array panel is approximately 100. If detection of a larger number of targets is desired, the sample can be analyzed sequentially with multiple panels of compatible antibody pairs [31] . Alternatively, larger arrays may be constructed with single-antibody detection using the direct-labeling approach (Fig. 1B) . In this format, fluorescence or biotin labeling of target proteins is employed in lieu of introducing detection antibodies [32] . Because the cross-reactivity is eliminated in the label-based format, array densities can be scaled up to a theoretically unlimited size. Both the label-based method [33] and the sandwich-based method [34] have proven valuable in the discovery of disease biomarkers.
The solid supports used in the fabrication of planar cytokine antibody arrays include glass or plastic slides, ELISA plates, and nitrocellulose membranes. Nitrocellulose and chemically activated or polymer-coated glass microscope slides are most commonly used supports. Membrane-based arrays typically have chemiluminescent readouts, making them a favorable, low cost option that is easily adaptable to existing Western blot detection systems. Glass-slide-based arrays provide the advantage of miniaturization; the surface can accommodate minute amounts of capture antibody (spots <200 m in diameter), thereby reducing the array size and the sample volume required [35] . Smaller array size then allows multiple arrays to be printed on one chip, making them suitable for high-throughput (HT) analysis [36] . Each 25 mm x 75 mm glass chip can accommodate thousands of antibody spots using current contact or non-contact array printers.
Fluorescence is by far the most commonly used readout system for glass-slide-based arrays [37] [38] [39] [40] , offering high signal stability and wide dynamic signal range. That being said, assuming one has access to compatible detection system, obtaining array spot signal intensities for any of these array formats (glass slide, membrane or ELISA plate) could be accomplished using fluorescence or chemiluminescence detection. For example, the Li-Cor Odyssey scanner (Li-Cor Biosciences, Lincoln, Nebraska), which detects infrared (IR) fluorescence, is compatible with semi-quantitative glassslide and membrane-based antibody arrays by substitution of the standard reporter with an analogous IR fluor.
Currently, there are several companies which manufacture cytokine antibody arrays. The commercial availability of cytokine antibody arrays greatly facilitates their widespread applications as biomarker discovery tools. See Table 3 for a summary of cytokine antibody arrays, categorized in terms of solid support (platform), detection method and type of immunodetecton employed (design principle). Please note that these categories represent 3 different properties of any given antibody array and can potentially be applied in any combination (e.g., any of the detection methods listed can be used with membrane-based arrays, which may be based upon any of the three design principles.) For example, it is theoretically possible to detect array signals in the ELISA-plate format using fluorescence; however, at the time of this publication, all commercially available arrays for the ELISAplate format used only chemiluminescence or electrochemiluminescence detection. This is because the available fluorescence scanners that were compatible with the ELISAplate format were expensive and, therefore, uncommon.
BIOMARKER DISCOVERY AND DEVELOPMENT PLATFORMS
Biomarkers include biological molecules, such as proteins, DNA or mRNA, which can be measured to indicate normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention. Biomarkers can have a transformative impact on health care. Early diagnostic biomarkers can identify disease at early stages, drastically reducing mortality rates. Predictive biomarkers may also help match the individual treatment to different patients suffering from same type of disease. Prognostic biomarkers can help to predict the outcome of patients. Biomarkers can also be critical components in drug discovery and development programs by identifying new drug targets or by serving as a surrogate marker for drug efficacy.
Since cytokine dysregulation is implicated in numerous pathologic processes, cytokines have been extensively investigated as potential biomarkers. Many such studies have utilized ELISA to assess individual cytokine levels. However, because this approach greatly restrains the progress of biomarker discovery, many researchers have turned to proteomics in an attempt to screen entire proteomes for diseasemediating proteins. That being said, no assay is perfect for all applications, and antibody array technologies are no exception.
A significant challenge to the development of antibody arrays is the availability of large numbers of antibodies with appropriate specificity and range of sensitivity [41] [42] [43] . Not only is the pool of array probes largely limited to available monoclonal and polyclonal antibodies, but each antibody must be carefully validated for performance and compatibility in microarray format, which limits the pool further. Any proteins detected using an immunoassay, including antibody arrays, would necessarily be ones that have previously been identified and for which antibodies have been produced. As such, any biomarkers identified using immunoassays will not be "novel" proteins. This underscores the need for largescale development of new antibodies to a wider range of proteins. Because traditional monoclonal and polyclonal antibodies are laborious and time-consuming to produce, recombinant antibody phage-display libraries are currently being explored as an alternate source of molecular probes [44] [45] [46] .
Two other challenges in applying proteomics to the discovery of disease biomarkers are the complexity of human biological fluids and the wide range of abundance of each of their constituents. Serum and plasma for instance, may contain more than 100,000 proteins, many of which exist at very low abundance (pg/ml range or lower) [47] . For example, there is no single dilution of serum or plasma samples that can result in detection of all cytokines present within the linear range of the antibodies used to detect them. In plasma or serum, many cytokines are present at low pg/ml concentrations (10 pg/ml or less); this is particularly true for pro-inflammatory proteins. However, the normal serum/plasma concentrations of adiponectin are in the μg/ml range, over 1 million-fold difference [48] . By contrast, antibody-based detection assays typically have an effective concentration range of about 1000-to 10,000-fold. Thus, optimized detection of a given set of cytokines in serum or plasma may require separation of antibody panels according to concentrations of the various cytokines to be detected.
Another significant challenge to the application of antibody arrays is sample-dependent interference. This interference may be represented by high background (usually attrib- utable to non-specific binding of sample proteins to the array surface) or matrix effects. In the context of an immunoassay, the latter is a general term describing disruption of antigenspecific interactions by one or more components of the sample itself. For example, the epitope on a target molecule may be blocked because of interaction of the target protein with another protein in the sample or an auto-antibody to the same target. However, the challenge of matrix effects and disparate concentrations of cytokines are not unique to antibody arrays; these challenges plague more traditional methods of proteomics as well [47] .
Until now, the majority of proteomic research has been undertaken using the classical methods of single or tandem mass spectrometry (MS/MS), which must be preceded by laborious fractionation techniques (2-dimensional gel electrophoresis or liquid chromatography) to deplete highabundance proteins. However, these separation techniques result in low reproducibility and sensitivity [49] ; [50] . This drawback, along with the low detection sensitivity of MS/MS, has hampered the success of these traditional proteomic methods in identifying valuable biomarkers. Yet another difficulty is the necessity to subsequently develop immunoassays to validate those proteins identified.
The emergence of antibody microarrays 11 years ago [51] has sought to address these limitations. Following the same concept as the DNA microarray, cytokine antibody arrays are an affinity-based proteomic method employing antibodies as probes instead of nucleic acids. Cytokine anti- Can only compare 2 samples Clontech, Sigma-Aldrich body arrays are now widely recognized as a reliable and robust methodology for mining complex biomarkers. In addition to eliminating the need for separation and depletion techniques, the high sensitivity of antibody probes allows for HT and high-specificity detection at pg/ml levels. Since antibody arrays by necessity use well-characterized antibodies as capture agents, immunoassays for individual targets are easily implemented for validation. Thus, biomarker discovery can advance seamlessly and rapidly from discovery phase to validation phase. Cytokine antibody arrays offer the additional advantages of much higher detection sensitivities, lower cost, and ease of use compared with the MS-based approach. For these reasons, cytokine antibody array technology has been widely used in biomarker discovery programs. Specific examples of such applications are discussed in the following sections.
CYTOKINE ANTIBODY ARRAYS IN NEUROLOGI-CAL & NEURODEGENERATIVE DISEASE BIO-MARKER DISCOVERY
Cytokine antibody arrays can provide insight into complex disease processes. Unfortunately, for many neurological and neurodegenerative diseases, very few details of the disease process are fully understood. One example of the use of antibody arrays to explore the molecular basis of disease is an investigation of the role of neuroinflammation in autism [52] . Autism is a neuro-developmental disorder resulting in a wide range of symptoms which include repetitive behavior and impaired social interactions. Although the etiology of autism is still enigmatic, an inflammatory mechanism had long been suspected. To investigate the correlation between symptoms of autism and neuronal inflammation, Vargas, et al., used a cytokine antibody array to screen for inflammatory factors in the CSF and brain lysates of autistic patients compared with age-matched normal controls.
The results showed consistently higher expression of MCP-1 and TGF 1, among other cytokines, in various regions of the brains of autistic patients. This study was the first to implicate neuroinflammation in the etiology of autism, and the results gave a clear indication of which proteins might be mediating it. Without a cytokine screening tool such as the cytokine antibody arrays, researchers would have had to correctly select individual antibodies for Western blots or ELISA to find the key factors of neuroinflammation. By using the predetermined panel of cytokine antibodies in the array, the authors were able to efficiently screen their precious biospecimens for inflammatory mediators. In so doing, they shone a light into a previously sealed black box.
The utilization of antibody arrays to detect biomarkers is well-illustrated in a landmark study by Wyss-Coray at Stanford on the key plasma markers of Alzheimer's disease [53] . In this study the authors describe how they used cytokine antibody arrays to discover plasma biomarkers specific for Alzheimer's. Their training set consisted of plasma samples from 43 patients with a previous Alzheimer's diagnosis (AD) and 40 age-and sex-matched non-demented controls (NDC). Results of the antibody array for each sample revealed salient differences in levels of the 120 proteins detected by the arrays. These differences were scored and distilled by crossvalidation into a predictive matrix of 18 markers able to classify patients as having Alzheimer's. Then the authors used two test sets to evaluate the predictive value of the 18 markers.
The first test set consisted of plasma samples from 42 Alzheimer's patients, 11 with other types of dementia (OD) and 39 non-dementia controls. Each sample was tested with the cytokine antibody arrays to simultaneously measure 120 cytokine levels and used a prediction analysis of microarray (PAM) scoring matrix based upon the expression of the 18 markers to classify the patients. Using this method, they were able to correctly identify the clinical diagnosis of these patients with 89% accuracy (90% agreement for those with Alzheimer's, 88% agreement for non-Alzheimer's).
The second test set consisted of plasma from 47 presymptomatic patients (patients with mild cognitive impairment (MCI)). While not every patient with MCI will ultimately progress to Alzheimer's, MCI can be an early warning sign of Alzheimer's for some patients. The authors tested archived plasma samples from patients with symptoms of MCI who were followed longitudinally. Some were subsequently diagnosed with Alzheimer's, and some with other types of dementia. Using the same PAM scoring method, they analyzed the results of these tests to see which of the 47 patient's cytokine expression profiles predicted an Alzheimer's diagnosis. The authors were able to predict which patients were ultimately diagnosed with Alzheimer's with 81% accuracy (91% agreement with Alzheimer's patients and 72% for non-Alzheimer's patients). Moreover, the plasma samples were taken up to 6 years before clinical diagnosis with Alzheimer's. These results suggest that the 18-marker panel may be useful as an early screening test for Alzheimer's.
This seminal report not only describes the discovery of a blood test for Alzheimer's, but also illustrates a broad strategy for screening for disease biomarkers, providing a roadmap for future biomarker investigations using antibody array technologies.
Dr. Wyss-Coray's group continues to pioneer the use of antibody arrays and novel methods of data analysis in search of biomarkers for neurodegenerative diseases. In a recent investigation by Wyss-Coray and Philipp Jäger, protein expression profiles for 776 secreted cytokine signaling factors were screened in plasma of patients with sporadic Alzheimer's compared to those of healthy controls. Statistical evaluation between the two groups using Significance Analysis of Microarray (SAM) algorithms revealed differential expression of 42 proteins among Alzheimer's patients including several previously associated with Alzheimer's, e.g., amyloid precursor protein (APP) and apo-lipoprotein E (ApoE). Their analysis also included the use of an elastic net regression algorithm (eNet) to identify even more potential plasma biomarkers. Further, they used connectivity and pathway analysis to identify the biological significance of the potential biomarkers, finding that most of them are involved in signaling pathways related to TNF , TNF or angiogenesis (personal communication).
CYTOKINE ANTIBODY ARRAYS IN IMMU-NOLOGICAL DISEASE BIOMARKER DISCOVERY
The human immune system is comprised of the innate and adaptive immune systems, both of which function to protect the individual from bacterial, viral, or parasitic pathogens. The innate immune system comprises physical barriers (such as skin and mucosa) and phagocytic cells (such as macrophages, granulocytes, dendritic cells, and natural killer cells). Upon activation, this system reacts rapidly by releasing a variety of inflammatory cytokines. The adaptive immune system is mediated through T-or Blymphocytes. Upon activation, T-cells can selectively proliferate into CD8+ cytotoxic effector cells, CD4+ T helper cells and long-lived memory cells, while B-cells develop into antibody producing plasma cells. There are many distinct subpopulations of CD4+ T helper cells with different cytokine profiles and distinct effector functions. Th1 cells produce IFN , IL-2 and TNF and promote cell-mediated immune responses involved in tissue damage and infection against intracellular parasites. Th2 cells produce IL-4, IL-5, IL-10 and IL-13 which are responsible for strong antibody production, eosinophilic inflammation, allergy and clearance of helminthic infections. Th17 cells produce IL-17, IL-17F, IL-21 and other inflammatory cytokines and play a role in host defense against extracellular pathogens as well as in autoimmune disorders. Cytokine antibody arrays have not only been used to study the gate-keeper cells (dendritic cells) of the immune system [54] , but have also been extensively used in all the three categories of human immunological disorders: autoimmunity, immunodeficiency and hypersensitivities.
Autoimmune diseases affect 3-8% of the world population, and comprise a wide variety of systemic or organspecific inflammatory diseases characterized by abnormal activation of immune cells to target self-tissues. The spectrum of autoimmune diseases includes rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), multiple sclerosis, systemic sclerosis (SS), type 1 diabetes, and psoriasis. The precise pathogenesis of most of the autoimmune diseases is still poorly understood, with disease diagnosis and classification relying mainly on clinical examination combined with traditional laboratory test and imaging studies. Inflammatory cytokines and chemokines appear to play a central role [55] .
SLE is a severe chronic autoimmune connective tissue disease, characterized by nuclear autoantibodies, formation of immune complexes and systemic vasculitis. There are currently no specific biomarkers for SLE diagnosis, classification, and monitoring of disease activity. Using protein microarray platform, Bauer, et al., identified a group of 30 interferon-regulated chemokines in the SLE subjects [56] . RA is characterized by chronic inflammation of the joints and subsequent loss of function. Hueber, et al., reported a panel of pro-inflammatory serum cytokines (IL-1 , IL-6, IL-13, IL-15, and TNF ) for early RA detection [57] . Through analysis of synovial fluid from early onset RA with antibody arrays, Raza, et al., found that a profile of T-cell derived cytokines was significantly elevated when compared with established RA patients, indicating the an active role of this cell type in disease pathogenesis [58] .
Crohn's disease (CD) is a chronic inflammatory bowel disease (IBD) of the intestines that may affect any part of the gastrointestinal tract from mouth to anus. It affects millions of individuals worldwide and causes a wide variety of symptoms such as abdominal pain, diarrhea, vomiting, or weight loss. While the exact cause of CD is unknown, overactive immune response to environmental and genetic factors or microorganisms is thought to be the main reason for chronic inflammation. Cytokines and chemokines play an important role in CD [59] . With a homemade 78-cytokine antibody array, Kader, et al., noticed that the serum levels of four cytokines (PLGF, IL-7, TGF 1, and IL-12p40) were elevated in CD patients in clinical remission versus active disease [60] . A 23-plex cytokine antibody array was also applied to monitor the peripheral immune response in CD patients during remission induction therapy with Infliximab, an anti-TNF antibody [61] .
Cytokine antibody arrays have been reported in many publications as a useful tool to study the complexity of immunodeficiency diseases. Through analyzing the profile of 120 cytokines, chemokines and growth factor in human CSF, Meeker, et al., showed that an increase of inflammatory cytokines and chemokines in HIV-infected patients correlated poorly with neurological status [62] . However, the severity of neurological disease correlated very well with the decline in growth factors, especially neurotrophin-3 (NT-3), indicating the loss of neuroprotection in HIV-infected patients.
Antibody arrays have also been used in the cell mediated type IV hypersensitivity such as graft-versus-host disease (GVHD) [63] . GVHD is a common complication of allogeneic bone marrow transplantation in which functional immune cells in the transplanted marrow recognize the recipient as "foreign" and mount an immunologic attack. GVHD can also occur with solid tissue transplants if the solid tissue is rich in lymphatic cells. While no validated biomarkers exist for the diagnosis of acute GVHD, Paczesny, et al., reported that a panel of 4 serum proteins (soluble IL-2 receptor (IL-2R ), soluble TNF receptor I (TNFRI), IL-8, and hepatocyte growth factor (HGF)), identified by screening 120 serum proteins with antibody array, were able to confirm the diagnosis of GVHD and provide prognostic information independent of GVHD severity.
CYTOKINE ANTIBODY ARRAYS IN ASTHMA BIO-MARKER DISCOVERY
Asthma is a disease characterized by remodeling of airway epithelium, which permanently obstructs airflow and by chronic inflammation of the small and medium airways. This inflammation contributes to hyperresponsive bronchoconstriction upon exposure to irritants or allergens, leading to an asthma attack. Currently, there is no single serological biomarker used in routine clinical asthma diagnosis and prognosis. However, multiple serum proteins such as eosinophil cationic protein (ECP), PARC (CCL18), TARC, HC gp-39, and fibrinogen have been described as potential biomarkers in pulmonary research [64] . Fibroblast growth factors (FGF), HGF, and stem cell growth factor beta (SCGF ) have also showed promise in a cytokine antibody array study [65] . Because of the importance of inflammation in the pathophysiology of asthma, several studies have focused on inflammatory biomarkers of asthma in both the sputum and exhaled breath condensates of affected individuals.
In the example of Kim, et al., the authors used a cytokine antibody array to examine the expression profiles of cytokines in the sputum of asthma patients compared to nonasthmatic control patients [66] . They found that, among others, expression of chemokines GRO (CXCL1), Eotaxin-2 (CCL24) and PARC (CCL18) were significantly higher in asthma patients. In addition, the authors noted that PARC levels were highly correlated with the relative number of eosinophils in sputum samples. Elevated eosinophil count is known to be associated with asthma, so the high correlation of PARC with eosinophil counts suggested a role for this chemokine in the pathogenesis of asthma.
In another investigation of the role of inflammation in asthma, antibody arrays were used to analyze cytokine expression patterns in exhaled breath condensates from normal and asthmatic individuals [67] . Since asthma is known to be an inflammatory disease, it was no surprise that inflammatory markers were expressed at higher levels in asthmatic patients. What was surprising was the correlation of the expression of inflammatory markers with patient symptoms. The authors compared the expression patterns with standard measures of patient symptoms, including forced expiratory volume in 1 second (FEV 1 ) and hyperresponsiveness to irritant challenge. RANTES (CCL5) expression correlated to FEV 1 , and TNF and TGF 1 expression correlated to airway hyperresponsiveness. Moreover, there was a linear correlation between the two: the more severe the patient's symptoms, the greater the concentration of the cytokines detected. This same group followed up on this study by proving that contamination by saliva in exhaled breath condensates was not responsible for the cytokines detected in these experiments [68] and extended their investigation of cytokine expression in exhaled breath condensates of asthmatic patients in response to standard therapies.
In one of these subsequent investigations, cytokine antibody arrays were used to compare cytokine profiles of asthmatic patients before (at baseline) and after commencement of corticosteroid therapy [69] . They then performed a statistical analysis of the pre-and post-treatment cytokine expression profiles in exhaled breath condensates. Patients with increased levels of IL-4 and RANTES along with decreased levels of IP-10 at baseline were much more likely to respond to treatment, as demonstrated by improvement in FEV 1 , a measure of airway obstruction. Also, improvement in FEV 1 following steroid therapy correlated well with decreased expression levels of IL-4 and RANTES. Taken together, this study identified elevated IL-4 and RANTES as biomarkers indicative of predicted positive response to steroidal therapy treatment and reduced levels of IL-4 and RANTES as biomarkers of successful treatment of symptoms by steroidal therapy. This illustrates two of the important uses of biomarkers in personalized medicine: prediction of response to treatment and monitoring progress during treatment. In a separate publication, this same group identified lower expression of RANTES in exhaled breath condensates in response to a combination of steroidal and leukotriene modifier therapy, particularly in patients with comorbid allergic rhinitis [67] .
CYTOKINE ANTIBODY ARRAYS IN CANCER BIO-MARKER DISCOVERY
Cancer is a disease driven by both genetic and epigenetic factors, leading to uncontrolled cellular growth, which manifests in altered signaling pathways including cell cycle deregulation, inhibition of apoptosis, blockage of differentiation, enhancement of angiogenesis, invasion and metastasis. Crosstalk among these pathways greatly influences the biological behavior of oncogenesis, i.e., its initiation, promotion, progression, metastasis and recurrence. Often these changes include changes in tumor microenvironment and resulting local inflammation [14] ; changes that may be revealed by alterations in protein profiling in sera and plasma of cancer patients. Therefore, evaluating changes in cellular protein profiling and identifying cancer-associated proteins between cancer and non-cancer patient samples could provide useful information for cancer diagnosis and treatment. The goal for cancer proteomics is to identify cancer-specific biomarkers for specific cancer types or specific cancer stages or responses for particular treatments.
Since cancer is a heterogeneous disease, it is unlikely that a single biomarker will detect all cancers of a particular organ with high specificity and sensitivity. For example, prostate-specific antigen (PSA) is a biomarker for prostate cancer with high sensitivity yet low specificity. CA-125 (also known as Mucin 16) is a biomarker for ovarian cancer with high sensitivity and low specificity. It is widely agreed that high specificity is the key performance issue for a successful cancer screening marker. Due to the prevalence rate of many cancer types, even a small false positive rate in a screening biomarker assay will translate a large number of costly and unnecessary diagnostic procedures as well as unwarranted stress for the patient. Therefore, rather than using a single marker, a multi-marker assay may be better suited for potential cancer screening with high sensitivity and specificity.
Antibody array technology has emerged as a promising platform for cancer biomarker discovery due to its unique advantages, of high-throughput quantification, low sample consumption, ease of use, and cost-effectiveness [70, 71] . Antibody arrays have been reported as cancer biomarker discovery platforms for several cancers, including ovarian cancer, prostate cancer, and breast cancer.
Among females in the US, breast cancer represents the leading cancer in incidence and the second deadliest cancer. Due to the heterogeneity of breast cancer, the search for multi-marker panels, which may lead to more accurate and reliable diagnosis, prognosis and treatment monitoring, has drawn much attention. There are a number of reports in which antibody array technology has been used to identify such multi-marker signatures. Yeretssian, et al., identified unique protein expression profiles in breast-cancer derived cell lines [72] . Hudelist, et al., identified a group of biomarkers by comparing protein expression in malignant and adjacent normal breast tissue from the same cancer patients [73] . Antibody arrays were also used to identify biomarkers for monitoring treatment response. Vazques-Martin, et al., reported the identification of an HER2-induced "cytokine signature" in breast cancer. Using cytokine antibody arrays, expression of 42 cytokines and growth factors were compared in conditioned media from MCF-7/HER2-18 (MCF-7 breast cancer cell line over-expressing HER2) and MCF-7/Neo control cells. Two biomarkers were identified with increased expression in MCF-1/Her2-18 cells (IL-8 and GRO ). The findings may represent novel biomarkers in monitoring breast cancer responses to endocrine treatments and/or HER2-targeted therapy [74] . Taken together, these studies strongly suggest that antibody array technology has shown great promise in the discovery and development of breast cancer biomarkers.
Ovarian cancer represents the third most frequent cancer and is one of the leading causes of cancer death among females in the US and Europe. Due to a lack of obvious symptoms, almost 80% of ovarian cancer patients are diagnosed at later stages. Unfortunately, the 5-year survival rate for patients with clinically advanced ovarian cancer is only 15% to 20%. By contrast, the 5-year survival rate for patients with stage I disease is over 90%. Therefore, it is of utmost importance to discover and develop biomarkers for ovarian cancer screening and early detection. Currently, CA-125 and imaging are the two most common tests for ovarian cancer screening. However, using a cutoff of 30 to 35 units/mL, serum CA-125 has demonstrated a specificity of only 50% to 60% and a sensitivity of >98% for early-stage ovarian cancer [75, 76] . Multiple studies have reported identification of ovarian cancer biomarkers using antibody array technology. Using biotin-label-based antibody arrays, we screened the serum expression profiles of 507 proteins in serum samples from 47 patients with ovarian cancers, 33 patients with benign ovarian masses and 39 healthy, age-matched controls. A panel of protein expression showed significant difference between normal and cancer (P<0.05). By classification analysis and split-point score analysis of these two groups, a six-marker panel of proteins (IL-2R , endothelin, osteoprotegerin, vascular endothelial growth factor D (VEGF-D) and betacellulin (BTC)) could be used to distinguish ovarian cancer patients from normal subjects [33] . Those studies strongly suggest that antibody array technology has great promise in the discovery and development of ovarian cancer biomarkers.
Prostate cancer is the most common cancer, with the second highest mortality rate of any cancer in the US. Strategies to inhibit prostate cancer metastasis include targeting both tumor-induced osteoblastic lesions and underlying osteoclastic activities. To identify the mechanism by which prostate cancer induces osteoclastic activity, Lu, et al., profiled cytokine expression in conditioned media from primary prostate epithelial cells, prostate cancer cells (LNCaP) and its derivatives (C4-2B and PC3 cells) with an antibody array detecting expression 174 cytokines. A panel of cytokine markers with increased expression in cancer and cancer derived cells was identified (MCP-1, IL-6, IL-8, GRO , ENA-78, CXCL16). The results may provide novel therapeutic targets for treatment of prostate-induced bone metastasis.
In order to find biomarkers for monitoring cancer vaccine efficacy, Toh, et al., measured expression profiles of 507 proteins using biotin-label-based antibody array in cultures of dendritic cells obtained as from colorectal cancer patients, both before vaccination and at 2 months and 4 months postvaccination [77] . When samples were compared from postvaccination (month 2 and 4) and pre-vaccination, 58 and 47 differentially expressed proteins were identified, respectively. Among them, 28 proteins showed consistent increased expression in both post-vaccination time points. Furthermore, using cytokine antibody arrays, a panel of 4 proteins were identified as markers to distinguish vaccine responders from non-responders (CXCL11, L-selectin, MCP-1 and soluble gp130). The results may represent a novel method for monitoring vaccine treatment efficacy in cancer patients.
SUMMARY AND FUTURE PROSPECTS

Application of Cytokine Antibody Arrays in Biomarker Discovery in Many Diseases
Disease biomarkers are among the most actively researched topics in biomedicine. Examples of molecular biomarkers include DNA, mRNA, microRNA, proteins and metabolites. Since the completion of the Human Genome Project, many researchers have looked for genetic markers suitable for diagnosing a disease, assessing a patient's risk of developing a given disease, or predicting the patient's response to a specific treatment. Inborn errors in metabolism and other rare genetic disorders, such as cystic fibrosis and sickle-cell anemia, can be definitively diagnosed by the presence a single gene or allele.
Additionally, protein functions may be influenced by post-translational processing (such as glycosylation. phosphorylation or proteolytic cleavage) or interactions with other proteins, all of which can be detected using antibody array technologies. Thus, characterizing the proteome may give a more realistic view of the biological status of the patient than genomic markers or gene expression [78] .
Although protein biomarkers can be found in many different types of patient specimens, blood samples have greatest potential for discovery of diagnostic and predictive biomarkers. Blood perfuse all tissues of the body and carries not only plasma-specific proteins but also proteins derived from other tissues. The proteins circulating in the blood are in a state of dynamic change, reflecting the health status of the individual. By contrast, an individual's genome is stable and unchanging. Thus, changes in proteins (and perhaps metabolites) may provide more valuable information for patient's treatment than genomic profiles.
Since the first demonstration that cytokine antibody arrays could detect proteins in complex biological samples with high sensitivity and specificity [79] , cytokine antibody arrays have been widely used in biomarker discovery and development programs, including the application of biomarkers as drug targets, or as predictive, diagnostic, or prognostic tools. Cytokine antibody arrays have been successfully used with many different biological sample sources, including serum [80] [81] [82] [83] , urine [84] [85] [86] , plasma [87, 88] , bronchoalveolar lavage [89] , gingival crevicular fluid [90] , synovial fibroblast supernatants [91] , CSF [92] , sputum [93] ; [94] , tears [95] , laser capture-microdissected tissue [96] , cell lysates [97] , tissue lysates [98] , conditioned medium [99] , liver cyst fluids [100] , saliva [101] , breast interstitial fluid [102] and many others.
In addition to those diseases and applications mentioned elsewhere in this review, cytokine antibody arrays have also been used to identify biomarkers for chronic obstructive pulmonary disease [93, 94] , transplantation [86] , endome-triosis [104] , irritable bowel syndrome [105] , periodontal diseases [106] , chronic kidney disease [103] , cystic fibrosis [82] , ulcerative colitis [83] , renal systemic lupus [87] , response to anti-retroviral therapy for AIDS [88] , many other types of cancers [107] [108] [109] [110] and many other diseases [111] .
Biomarkers in Clinical Applications
Recently, NIH has made biomarker discovery and validation a cornerstone of its support of translational research, meant to bridge the gap between bench science and clinical applications, and it has devoted considerable resources to support it. However, the translation of biomarkers into more effective patient care and better outcomes remains a challenge. There are still many obstacles to developing clinically useful biomarkers, including technical challenges associated with pre-analytical variables and validating potential biomarkers in larger and unbiased clinical tests. The ability to simultaneously detect multiple proteins greatly facilitates the biomarker discovery progress. Indeed, the discovery of biomarkers using the antibody array technology has increased tremendously in recent years.
One of major advantage of antibody array-based biomarker discovery and development is the seamless transition of biomarker discovery to validation. Many biomarker validation processes are performed by industry and may not be published in the literature. An unknown percentage of biomarkers fail in the validation stage; therefore, it is difficult to estimate how many biomarkers have been validated after the discovery phase. Furthermore, the FDA has approved very few biomarkers for clinical use. Diagnostics employing a single biomarker may lack the specificity needed for FDA approval. However, the use of multiple biomarkers in a panel may improve the overall positive predictive value. Pharmaceutical companies are increasingly interested in developing companion biomarker tests to pre-screen patients to predict whether a given patient will respond to a given therapeutic (personalized medical) or to monitor the patient's response to treatment.
With the advent of new and improved protein chip technologies, it is foreseeable that the application of protein arrays in biomarker program will accelerate translation of biomarkers into clinical practice.
Array Detection Technology
The increased use of protein and antibody arrays (including cytokine antibody arrays) in biomarker discovery programs has spurred the advancement of various detection technologies. With improved sensitivities now being achieved by sandwich-based and label-based techniques, they continue to be the preferred method of detection in cytokine antibody arrays. Because paired antibodies are required in sandwich-based detection technology and labeling agents or tags can introduce artifacts in label-based detection technology, (masking epitopes or altering protein functionality), the use of label-free detection in antibody arrays is gaining attention. Many new label-free technologies are emerging in this field [112] [113] [114] , including surface plasmon resonance (SPR) [115] , planar waveguide technology [116] , electrochemical detection [117] , quartz crystal microbalance (QCM) [118] [119] [120] and microcantilevers [121, 122] . Other label-free technologies including biosensors of carbon nanowires and nanotubes, which detect changes in conductivity on the surface upon binding, can also be used in protein array detection.
Without the interference of tagging agents, label-free multiplexed protein arrays will ensure detection of proteins with native conformations and functionalities. Furthermore, label-free technologies will provide quantitative data such as affinity constants and kinetic parameters, among others. To date, most studies of label-free detection technology have made use of ideal model systems for proof-of-concept experiments. However, as detection sensitivities improve and equipment costs are reduced, this trend should gradually change in the years to come and label-free techniques may be used for the detection and study of more general biological interactions.
Since in label-based or label-free systems only one antibody is used, specificity of the antibodies employed is paramount, and cross-reactivity of antibodies to other proteins becomes a greater concern than with sandwich-based detection. Therefore, the development of systems suitable for conclusive validation of biomarkers will certainly increase the reliability of assay. MS-based antibody arrays represent one possible solution. The limitations of MS-based approach are low sensitivity and difficulty in quantification. To overcome this problem, a surface plasmon resonance coupled to MS (SPR-MS) array platform has been developed. In this format, antibody arrays are used to capture the corresponding targets from biological samples. The nature of captured protein is further validated by MS and quantified by SPR [123, 124] . Such MS-based antibody arrays offer dual specificity, which is resulted from by the affinity of antibody and the protein mass readout. Furthermore, the MS aspect of the analysis provides simultaneous detection of protein isoforms, modifications and interaction in a single step. The combination of high-content and high-throughput of antibody arrays, labelfree and real time detection of SPR and protein-specific mass spectra of MS provides an ideal system for simultaneous quantitative measurement of multiple protein levels, different isoforms of a protein and protein modifications with high specificity. Although at this moment, the detection sensitivity of this approach is still much lower than label-based approach and sandwich-based approach, and sophisticated equipment is needed. As the advance of technology, the combined approach represents the future of profiling of multiple proteins, particularly in the biomarker discovery phase.
New Technologies on the Horizon
One way to speed up biomarker discovery and validation would be to develop microfluidic devices, which would require only a few microliters of samples. Moreover, microfluidic techniques are amenable to automated testing, allowing for high-throughput applications. Dr. Heath's group have developed a platform which can detect a dozen cytokines with high specificity and sensitivity [125] . Their system has demonstrated detection of cytokine expression in a single cell. Due to the rapidity of the assay and its low sample consumption, microfluidic devices may have applications in clinical diagnosis and managing patients' care.
Recently, Dr. Wang at Stanford University invented an innovative magnetic nanosensor detection technology to measure multiple serum proteins including cytokine from diverse biological samples [126] . In this platform an array of giant magnetoresistive (GMR) sensors is used to detect protein binding events by surface-bound antibodies. In the sandwich-based format, the capture antibody is bound to the sensor and the detection antibody is tagged with a superparamagnetic nanoparticle. Under an external magnetic field, the nanoparticles become magnetized and can be detected by the underlying GMR sensor. As demonstrated by the authors, this platform offers several important advantages over the previous technologies. It is insensitive to matrix effects due to heterogeneity in ionic strength, pH, temperature and autofluorescence. Protein concentrations as low as 50 attomolar (10 -18 ) can be detected, making it at least 1000 times more sensitive than ELISA. The authors claimed that magnetic nanosensors are at least comparable to the most sensitive biosensors. Furthermore, it can achieve detection dynamic ranges over six orders of magnitude.
Current technologies of fabrication of protein and antibody arrays produce typical spot sizes of 100-200 microns (μm). Thus, applications of these are limited to sample volumes of at least 50-100 μL. To reduce the volumes of reagents and samples used in these arrays and incubation times, many new technologies are under development to fabricate the arrays with very small spot sizes (usually from 50 nm to 400 nm). Among them are dip pen lithography [127] , porphyrin-based photocatalytic lithography [128] , imprint lithography [129] , block co-polymer formation [130] .
In summary, cytokine antibody arrays have been emerging as an effective tool in biomarker discovery. As the technology matures, more biomarkers will be discovered and validated using cytokine antibody arrays.
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